Improved Therapeutics for the Resurrection of the Aged Form of Acetylcholinesterase
老化乙酰胆碱酯酶复活的改进疗法
基本信息
- 批准号:9977281
- 负责人:
- 金额:$ 40.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-15 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylcholineAcetylcholinesteraseActive SitesAgingAmmoniumBackBindingBinding SitesBiochemicalChemical AgentsChemical Warfare AgentsChemicalsCleaved cellComplementComputing MethodologiesCountryCrystallizationDockingEnzymesEventExposure toFamilyHumanIn VitroKineticsLeadLibrariesLigandsMechanicsMethodsMilitary PersonnelMolecularNeuromuscular JunctionOrganic SynthesisOrganophosphorus CompoundsOximesPeripheralPesticidesPharmaceutical PreparationsProcessPropertyProteomicsReportingSerineSocietiesSomanStructureTestingTherapeuticVariantadductage effectagedcholinergicdesignhumanized mouseimprovedin silicoin vivomass casualtymedical countermeasuremethylphosphonatemolecular dynamicsmouse modelnerve agentnovelquantumquinone methidereceptorscaffoldscreeningsmall molecule librariessuccesstoxicant
项目摘要
One of the major deficiencies of current medical countermeasures is that current oximes cannot
reactivate nerve agent-inhibited acetylcholinesterase (AChE) that has aged after exposure to
organophosphorus G- and V-type chemical nerve agents. Our team has demonstrated the first, and
only, compounds that have the capability to “resurrect” in vitro the methylphosphonate-aged
form of AChE to an active, native state. We posit that this resurrection accomplishes two distinct steps
– first, to realkylate the anionic aged form back to a neutral, phosphylated (inhibited) serine residue and
then to reactivate the inhibited form back to the native AChE. This proposal focuses on expanding on
these successful chemical frameworks in order to identify even more efficacious drug-like molecules that
will enable the aged form of AChE to be resurrected in vivo. Using various quinone methide precursor
(QMP) frameworks, we will use computational and experimental approaches to prepare a chemical
library and then to screen these compounds for efficacy in resurrecting the aged form of AChE back to
native activity.
There are no approved countermeasures that can resurrect the aged form of AChE to its active form;
however, resurrection of aged AChE is the holy grail against OP exposure. If realkylation of aged AChE
can occur, then AChE can be fully rejuvenated as oximes (and other reactivators) exist that are potent
nucleophiles for cleaving the O–P bond of the phosphylated serine, thereby reforming active AChE.
Thus, the objective of this proposal is to expand on our successful chemical frameworks to react
selectively with aged AChE to form stable alkylphosphonate-AChE adducts that can then be
reactivated to the native state, thereby reversing the effects of aging by chemical nerve agents.
The design of alkylating compounds will be guided by state-of-the-art computational methods (molecular
dynamics, molecular docking, and quantum mechanical methods) that predict the ligand-receptor
interactions of alkylating compounds with aged AChE. Using in silico guidance, libraries of alkylating
quinone methide precursor (QMP) compounds will be synthesized, and then tested in a kinetic screening
process, and complemented by mass spectrometric and proteomic studies. The best lead compounds
will be evaluated for their in vitro drug-like properties and tested in vivo in a humanized mouse model for
AChE.
当前医学对策的主要缺陷之一是当前肟不能
重新激活神经毒剂抑制的乙酰胆碱酯酶(AChE),
有机磷G型和V型化学神经毒剂。我们的团队已经展示了第一个,
只有那些能够在体外“复活”甲基膦酸酯老化的化合物,
AChE的形式到一个积极的,自然的状态。我们认为这次复活完成了两个不同的步骤
- 首先,将阴离子老化形式再烷基化回到中性磷酸化(抑制)丝氨酸残基,
然后将被抑制的形式重新激活为天然AChE。该提案的重点是扩大
这些成功的化学框架,以确定更有效的药物样分子,
将使老化的乙酰胆碱酯酶在体内复活。使用各种醌甲基化物前体
(QMP)框架,我们将使用计算和实验方法来制备一种化学物质
库,然后筛选这些化合物的功效,使AChE的老化形式恢复到
本土活动。
目前还没有得到批准的对策可以使老化的乙酰胆碱酯酶恢复到其活性形式;
然而,老化AChE的复活是对抗OP暴露的圣杯。如果老化AChE的再烷基化
可以发生,那么AChE可以完全恢复活力,因为肟(和其他再活化剂)存在,
亲核试剂用于切割磷酸化丝氨酸的O-P键,从而重整活性AChE。
因此,本提案的目的是扩大我们成功的化学框架,
选择性地与老化的AChE形成稳定的烷基膦酸酯-AChE加合物,
重新激活到自然状态,从而逆转化学神经毒剂的衰老效应。
烷基化化合物的设计将由最先进的计算方法(分子
动力学、分子对接和量子力学方法)来预测配体-受体
烷基化化合物与老化AChE的相互作用。使用计算机指导,烷基化库
醌甲基化物前体(QMP)化合物将被合成,然后在动力学筛选中进行测试
过程,并辅以质谱和蛋白质组学研究。最好的铅化合物
将评估它们的体外药物样性质,并在人源化小鼠模型中进行体内测试,
疼.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher M. Hadad其他文献
On the encapsulation of hydrocarbon components of natural gas within molecular baskets in water. The role of C-H···π interactions and the host's conformational dynamics in the process of encapsulation.
天然气中碳氢化合物组分在水中分子篮的封装过程中C-H·π相互作用和主体构象动力学的作用。
- DOI:
10.1039/c4cc04107k - 发表时间:
2014 - 期刊:
- 影响因子:4.9
- 作者:
Y. Ruan;P. W. Peterson;Christopher M. Hadad;J. Badjić - 通讯作者:
J. Badjić
Molecular docking and biological evaluation of a novel IWS1 inhibitor for the treatment of human retroperitoneal liposarcoma
一种新型 IWS1 抑制剂治疗人类腹膜后脂肪肉瘤的分子对接及生物学评价
- DOI:
10.1038/s41598-025-07215-y - 发表时间:
2025-07-02 - 期刊:
- 影响因子:3.900
- 作者:
Marina Goryunova;Yiran He;Carson Karakis;Elizaveta K. Titerina;Ana I. Salazar-Puerta;Sayumi Tahara;Nipin Sp;Neil N. Thakkar;Orlando Cómbita-Heredia;Kavya Dathathreya;Alessandro La Ferlita;Yanping Xu;Zhentao Zhang;Raphael Pollock;Daniel Gallego-Perez;Hua Zhu;Christopher M. Hadad;Joal D. Beane - 通讯作者:
Joal D. Beane
Christopher M. Hadad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher M. Hadad', 18)}}的其他基金
Improved Therapeutics for the Resurrection of the Aged Form of Acetylcholinesterase
老化乙酰胆碱酯酶复活的改进疗法
- 批准号:
10238898 - 财政年份:2019
- 资助金额:
$ 40.58万 - 项目类别:
Reactivation of Aged Acetylcholinesterase: Design and Development of Novel Therap
老化乙酰胆碱酯酶的重新激活:新型疗法的设计和开发
- 批准号:
8735550 - 财政年份:2014
- 资助金额:
$ 40.58万 - 项目类别:
Reactivation of Aged Acetylcholinesterase: Design and Development of Novel Therap
老化乙酰胆碱酯酶的重新激活:新型疗法的设计和开发
- 批准号:
8913280 - 财政年份:2014
- 资助金额:
$ 40.58万 - 项目类别:
Enhancement of organophosphinate hydrolase activity therough mechanistic evaluati
通过机理评估增强有机次膦酸酯水解酶活性
- 批准号:
7235231 - 财政年份:2006
- 资助金额:
$ 40.58万 - 项目类别:
Photochemistry of Azide Based Cross-Linkers in Water
叠氮化物交联剂在水中的光化学
- 批准号:
7623586 - 财政年份:2006
- 资助金额:
$ 40.58万 - 项目类别:
Enhancement of organophosphinate hydrolase activity therough mechanistic evaluati
通过机理评估增强有机次膦酸酯水解酶活性
- 批准号:
7920099 - 财政年份:
- 资助金额:
$ 40.58万 - 项目类别:
Enhancement of organophosphinate hydrolase activity therough mechanistic evaluati
通过机理评估增强有机次膦酸酯水解酶活性
- 批准号:
7689884 - 财政年份:
- 资助金额:
$ 40.58万 - 项目类别:
Enhancement of organophosphinate hydrolase activity therough mechanistic evaluati
通过机理评估增强有机次膦酸酯水解酶活性
- 批准号:
7487881 - 财政年份:
- 资助金额:
$ 40.58万 - 项目类别:
Enhancement of organophosphinate hydrolase activity therough mechanistic evaluati
通过机理评估增强有机次膦酸酯水解酶活性
- 批准号:
8117144 - 财政年份:
- 资助金额:
$ 40.58万 - 项目类别:
相似海外基金
Effect of Acetylcholinesterase inhibitors on Bone Metabolism and Fracture Risk Factors among older adults with mild to moderate Alzheimer's Disease
乙酰胆碱酯酶抑制剂对患有轻至中度阿尔茨海默病的老年人骨代谢和骨折危险因素的影响
- 批准号:
10739853 - 财政年份:2023
- 资助金额:
$ 40.58万 - 项目类别:
Acetylcholinesterase Complex Protein-Protein Interactions as Drug Targets Against Organophosphate-induced Neurotoxicity.
乙酰胆碱酯酶复合物蛋白质-蛋白质相互作用作为抗有机磷诱导的神经毒性的药物靶点。
- 批准号:
10772738 - 财政年份:2023
- 资助金额:
$ 40.58万 - 项目类别:
Machine learning approaches to predict Acetylcholinesterase inhibition
预测乙酰胆碱酯酶抑制的机器学习方法
- 批准号:
10378934 - 财政年份:2021
- 资助金额:
$ 40.58万 - 项目类别:
Acetylcholinesterase Complex Protein-Protein Interactions as Drug Targets Against Organophosphate-induced Neurotoxicity.
乙酰胆碱酯酶复合物蛋白质-蛋白质相互作用作为抗有机磷诱导的神经毒性的药物靶点。
- 批准号:
10303546 - 财政年份:2021
- 资助金额:
$ 40.58万 - 项目类别:
Investigating the in vivo targets and mechanism of action of a toxic acetylcholinesterase-derived peptide upregulated in Alzheimer's disease
研究阿尔茨海默病中上调的有毒乙酰胆碱酯酶衍生肽的体内靶点和作用机制
- 批准号:
2480200 - 财政年份:2020
- 资助金额:
$ 40.58万 - 项目类别:
Studentship
Improved Therapeutics for the Resurrection of the Aged Form of Acetylcholinesterase
老化乙酰胆碱酯酶复活的改进疗法
- 批准号:
10238898 - 财政年份:2019
- 资助金额:
$ 40.58万 - 项目类别:
Elucidation of the cell protective mechanism of acetylcholinesterase variants in cardiomyocyte and approach to therapy for myocardial infarction
心肌细胞乙酰胆碱酯酶变异体的细胞保护机制的阐明及心肌梗死的治疗方法
- 批准号:
18K15850 - 财政年份:2018
- 资助金额:
$ 40.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Alzheimer's disease drugs inhibiting acetylcholinesterase on prion replication.
阿尔茨海默病药物抑制乙酰胆碱酯酶对朊病毒复制的影响。
- 批准号:
481759-2015 - 财政年份:2015
- 资助金额:
$ 40.58万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Reactivation of Aged Acetylcholinesterase: Design and Development of Novel Therap
老化乙酰胆碱酯酶的重新激活:新型疗法的设计和开发
- 批准号:
8735550 - 财政年份:2014
- 资助金额:
$ 40.58万 - 项目类别:
Brain-penetrating acetylcholinesterase reactivators for several organophosphates
几种有机磷酸酯的脑穿透性乙酰胆碱酯酶再激活剂
- 批准号:
8544717 - 财政年份:2014
- 资助金额:
$ 40.58万 - 项目类别: